MedTrace Logo

Alberta Lung Cancer Screening Program

NCT02431962 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2021-03-08

No results posted yet for this study

Summary

Lung cancer is the leading cause of cancer death in North America and in the world. The vast majority of lung cancers are associated with cigarette smoking. Unfortunately, the majority of lung cancers are detected at an advanced stage when they have a very poor prognosis. A substantial amount of data has been reported on low-dose computed tomography (LDCT) screening. Yet endorsement of lung cancer screening has not been universal because of outstanding concerns which need to be addressed. Our study will aim to screen at risk Albertans for lung cancer with LDCT scan at baseline, year 1 and year 2 while attempting to fill some knowledge gaps on this topic.

Conditions

  • Lung Neoplasms
  • Respiratory Tract Neoplasms

Interventions

PROCEDURE

Computed Tomography

Low dose chest CT screening annually x 3

BEHAVIORAL

Active smokers - Smoking cessation arm

Phone based smoking cessation counseling

BEHAVIORAL

Active smokers - Control arm

Subjects will be provided with general information on available smoking cessation resources

Sponsors & Collaborators

  • Alberta Cancer Foundation

    collaborator OTHER

  • University of Calgary

    lead OTHER

Principal Investigators

  • Alain Tremblay, MD · University of Calgary

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2019-12-31
Completion
2022-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02431962 on ClinicalTrials.gov